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1. Introduction 
Muscular dystrophies have historically been characterised according to clinical criteria, 
however in the genomic age the muscular dystrophies are now subdivided into groups 
according to the primary gene defect. Currently identified are 29 different loci and encoded 
proteins, giving rise to 34 distinct forms of muscular dystrophy (Dalkilic & Kunkel 2003; 
Hsu 2004). The majority of these types of muscular dystrophy are caused by perturbations 
of different components of the dystrophin-glycoprotein complex (DGC) an integral 
component of the cellular cytoskeleton (see below). Dystrophin is the largest component of 
the DGC and is absent in Duchenne muscular dystrophy (DMD), and severely truncated 
with decreased levels in Becker muscular dystrophy (BMD) (Hoffman & Kunkel 1989). 
DMD and the allelic BMD are the most common forms of muscular dystrophy in humans 
and together they are termed dystrophinopathies (Kingston et al. 1984; Shaw & Dreifuss 
1969). DMD alone accounts for approximately 80% of all the myopathies in the muscular 
dystrophy group (Culligan et al. 1998).The dystrophin gene is the second largest described 
to date, totalling 1.5% of the X chromosome, 0.1% of the entire genome. The DMD gene is 
99% introns, with a coding sequence of 86 exons (including the promoters) and remains the 
only known human metagene (Blake et al. 2002; Burmeister et al. 1988; Hamed & Hoffmann 
2006; Kenwrick et al. 1987; Koenig et al. 1987; Kunkel et al. 1986; Muntoni et al. 2003; Roberts 
et al. 1993; Smith et al. 2006; Van Ommen et al. 1987; Wallis et al. 2004). Dystrophin was 
demonstrated to be localised at the sarcolemma in human skeletal muscle after its’ genetic 
characterisation (Arahata et al. 1988; Sugita et al. 1988; Zubrzycka-Gaarn et al. 1988). This 
discovery was followed by a report of dystrophin messenger RNA in brain, with the protein 
being specifically localised at postsynaptic densities (PSD) in the CNS, in particular in the 
hippocampus, cerebral cortex and in cerebellar Purkinje cells (PC) (Chamberlain et al. 1988; 
Chelly et al. 1988, 1989;  Lidov et al. 1990, Nudel et al. 1988).  
From the earliest reports authors have noted a preponderance of cognitive impairment in 
the Duchenne population and it has been well established that the average IQ of the boys 
with DMD is 85, one standard deviation below the normal of 100 (Cotton et al. 2005). With a 
greater understanding of the underlying molecular biology i.e. genotype, the recognised 
phenotype of dystrophinopathies is expanding (Beggs 1997; Emery 2002, 2002a; Ferlini et al. 
1999; Muntoni et al. 1993). More recently investigations into the role of these proteins in the 
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CNS have commenced. In contrast to skeletal muscle, the function of dystrophin in brain is 
less well understood in part due to its more recent discovery in the CNS as well as the 
greater complexity of the dystrophin gene products and DGCs in this location (Culligan et 
al. 2001). It has been suggested that dystrophin may play a role in anchoring the 
postsynaptic apparatus, receptor channel clustering and membrane organization (Lidov et 
al. 1993). This anchoring of molecules, critical for neuronal function, may be achieved by 
dystrophin/DGC acting as adaptors between the actin cytoskeleton and membrane bound 
receptors (Yoshihara et al. 2003). It may also play a critical role in the formation and 
maintenance of macromolecular signalling complexes (Tokarz et al. 1998; Yoshihara et al. 
2003). Dystrophin has also been suggested to play a role in stabilizing the postsynaptic 
apparatus to maintain a certain status of the network after brain maturation and/or 
episodes of synaptic plasticity (Brunig et al. 2002). Calcium levels have been found to be 
abnormal in neurons from an animal model of DMD (mdx mouse), and in a situation 
analogous to muscle, this could make these cells more susceptible to necrosis (Culligan et al. 
2001). In summary, dystrophin deficiency may significantly alter membrane integrity, ion 
channel physiology, calcium homeostasis, regional cellular signal integration and structural 
reorganisation at the synapse (Mehler 2000; Vaillend & Billard 2002; Vaillend et al. 2004). 
The majority of recent studies support a role for dystrophin in organisation of the mature 
synapse – particularly GABA-ergic synapses under dynamic conditions. Below is a brief 
summary of the localisation of dystrophin/DGC in the CNS and a synthesis of the current 
literature investigating the role of dystrophin in human and murine CNS at the behavioural, 
morphological, biochemical and electrophysiological level.  
1.1 The dystrophin-glycoprotein complex in CNS  
Individual members of the DGC show a variety of site-specific specializations leading to 
many different DGCs (differentiated by binding-partner profile, localization and 
composition) existing in the CNS. Differences exist between the DGC in muscle and 
neuromuscular junction and also between both of these DGCs and brain DGCs. 
Additionally, individual members of the DGC play different roles at different sites. In the 
brain, unlike in muscle, the association of syntrophin with dystrophin is not crucial for DGC 
formation (Moukhles & Carbonetto 2001; Waite et al. 2009). Furthermore, Culligan & 
Ohlendieck (2002) have suggested that the brain DGC consists of four main components, the 
dystroglycan subcomplex, a dystrophin or utrophin gene product, a dystrobrevin isoform 
and a syntrophin subcomplex (Fig.1). Complexes including short dystrophin gene products 
together with syntrophin may also be expressed in both neurons and glia.   
A role for the DGC in CNS has been suggested by many investigators, yet unequivocal 
evidence has yet to emerge. One theory suggests a role for the DGC in cellular 
communication by acting as a transmembrane signalling complex (Muntoni et al. 2003; 
Petrof 2002; Rando 2001). Supportive evidence for this theory is seen when mutations of the 
DGC component genes leads to cell death, thought to be due to a disruption of cell survival 
pathways and cellular defence mechanisms, both of which are regulated by signalling 
cascades (Muntoni et al. 2003; Rando 2001). The DGC in CNS may also play a dual function: 
incorporating both membrane stabilization as well as transmembrane signalling, as has been 
demonstrated at the neuromuscular junction (Albrecht & Froehner 2002). Additionally, the 
DGC has been suggested to play a role in the structural/functional organisation and/or 
stabilization of synapses (Albrecht & Froehner 2002). Dystroglycan and dystrophin, as  
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Fig. 1. The molecular organization of the “DGC-like” complexes and associated proteins in 
neurons (Modified from Waite et al. 2009).  
central components of DGCs, have been implicated in the stabilisation of neurotransmitter 
receptor clusters e.g. GABAergic and cholinergic afferents (Knuesel et al. 1999; Zaccaria et 
al. 2001). It has been suggested that the DGC may act as a cytoskeletal scaffold on which 
signalling complexes as well as transmembrane proteins can be assembled and clustered, 
largely mediated by the syntrophins and dystrobrevins (Albrecht & Froehner 2002; 
Cavaldesi et al. 1999; Connors et al. 2004; Gee et al. 1998; Hashida-Okumura et al. 1999). 
Culligan and Ohlendieck (2002) propose that the extracellular component of neuronal DGCs 
mediates cellular signalling through interactions of specific proteins such as laminin, 
laminin α2, perlecan, agrin and biglycan. These interactions are believed to play a role in 
terminal consolidation, integrity and maintenance. Ceccarini et al. (2002) postulate that the 
DGC may play a role in the neuronal maturation process i.e. in morphological and 
functional modifications such as neurite outgrowth and synapse formation. Levi et al. (2002) 
suggest that the DGC may act as a trans-synaptic signal for some aspects of signalling 
involved in central neuron synaptic differentiation (Levi et al. 2002). 
2. Dystrophin and the CNS 
2.1 Localization 
Dystrophin expression in the CNS is significantly more complicated compared to muscle 
due to the site specificity, developmental expression and diversity of gene products in this 
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tissue. Levels of dystrophin in the brain are approximately 10% of those found in muscle. 
However, the CNS has the highest number of different dystrophin gene products of any 
other organ/tissue in the body (Abdulrazzak et al. 2001; Gorecki et al. 1991, 1992; Gorecki & 
Barnard 1995; Tokarz et al. 1998). Early studies indicated that in the CNS dystrophin 
localises primarily to the vascular endothelium, postsynaptic regions, pia and choroid 
plexus (Kamakura et al. 1994; Lidov et al. 1990; Uchino et al. 1994). Later studies 
demonstrated that Dp71 a smaller gene product of the dystrophin gene, is present in the 
wall of blood vessels, but is actually expressed in perivascular astrocyte endfeet (Ueda et al. 
2000). Nudel et al. 1998, Chelly et al. (1988 and 1989) and Chamberlain et al. (1988) found 
dystrophin messenger RNA in brain and suggested that the lack of dystrophin in DMD may 
be the cause of cognitive impairment known to exist in this population. Lidov et al. (1990) 
demonstrated that dystrophin was specifically localised at postsynaptic densities (PSD) in 
the CNS, in particular in the hippocampus, cerebral cortex and in cerebellar Purkinje cells 
(PC) in rodents. This is in agreement with others who also found Dp427 as well as Dp71 
enriched at the PSD (Blake et al. 1999; Jung et al. 1993; Kim et al. 1992; Moukhles & 
Carbonetto 2001). Uchino et al. (1994) confirmed these findings of PSD localisation in 
humans in agreement with Kim et al. (1995) and Jancsik & Hajos (1998). This latter group 
found that dystrophin was in the spines of neurons, with particularly heavy labelling at the 
PSD (Jancsik & Hajos 1998). There are now known to be three full-length dystrophin gene-
products found in the CNS: M-dystrophin has been found in cerebral cortex and 
hippocampus (CA1, CA2 and CA3), C-dystrophin has also been localised to the cortex (grey 
matter, parietal layers II-IV, cingulated cortex) and  hippocampus (pyramidal layer , layer II 
of infrahinal cortex, striatum radiatum and striatum oriens). C-dystrophin has also been 
demonstrated to be present in brainstem (inferior olive and trigeminal complex) and the 
midbrain (Caudate putamen). The third full-length dystrophin gene product P-dystrophin 
has been found in foetal cerebral cortex and Purkinje cells from early in the developmental 
process. Full-length dystrophin gene products are expressed almost exclusively in neurons 
(Lidov et al. 1990; Waite et al. 2009). The shorter dystrophin-gene products have a 
nomenclature of ‘Dp’ followed by their molecular weight: Dp 260 (D’Souza et al. 1995) Dp 
140 (Lidov et al. 1995), Dp 116 (Byers et al. 1993; Schofield et al. 1994) and Dp71 (Blake et al. 
1992; Iannello et al. 1991; formerly named apo-dystrophin 1 or G-dystrophin). Dp260 is 
found predominately in the retina (also brain and cardiac tissue) (Cibis et al. 1993; Costa et 
al. 2007; D’Souza et al. 1995; Pillers et al. 1993). Dp140 is predominately expressed in brain 
during foetal development and at very low levels in the adult brain, localised to astro-glial 
processes, vascular endothelium and leptomeningeal surfaces (Bardoni et al. 2000; Lidov et 
al. 1995). Dp 116 has been localised to adult peripheral nerves, along the Schwann cell 
membrane and fibroblasts (Byers et al. 1993; Labarque et al. 2008). Dp71 is expressed in a 
variety of tissues, predominately the CNS (where it is the most abundant dystrophin gene 
product), it has multiple isoforms each with specific subcellular localisations (Austin et al. 
1995, 2000; Bar et al. 1990; Blake & Kroger 2000; Ceccarini et al. 2002; Chamberlain et al. 
1988; Greenberg et al. 1996; Holder et al. 1996; Huard et al. 1992; Ilarraza-Lomeli et al. 2007; 
Lederfein et al. 1992;Miyatake et al. 1991; Rapaport et al. 1992). Dp71 has been localised to 
hippocampus (CA1 and dentate gyrus), olfactory bulb as well as perivascular astrocyte feet 
(Daoud et al. 2009). Figure 2 (modified from Blake et al. 2002) is a schematic diagram of the 
structure of dystrophin gene products. The basic structure consists of four main domains:  
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i. the N terminal which shares similarities to α-actin and has an actin-binding domain 
(Byers 1989; Fabbrizio et al. 1995; Koenig et al. 1988). 
ii. a central rod domain with 24 spectrin-like triple helical repeats conferring an extended 
rod shape interrupted by four proline-rich spacer domains thought to act as hinges and 
conferring flexibility (Arahata et al. 1988; Cross et al. 1990;  Koenig & Kunkel 1990, 
Michalak & Opas et al. 2001; O’Brien & Kunkel 2001; Roberts 2001).  
iii. Cysteine-rich domain, separated from the rod domain by a WW domain (a protein-
binding module found in several signalling and regulatory molecules). The cysteine-
rich domain encompasses the EF1, EF2 and ZZ domains which together are termed the 
dystroglycan-binding domain. Following the ZZ domain is an α-helical domain 
important in mediating interactions with syntrophin (Bork & Sudol 1994; Huang et al. 
2000; Ishikawa-Sakurai et al. 2004;  Jung et al. 1995;  Ponting et al. 1996; Rentschler et al. 
1999; Suzuki et al.  1994; Winder et al. 1995). 
iv. The C-terminal domain which contains binding sites for some dystrophin-associated 
glycoproteins, as well as putative sites for endogenous protein kinases to act upon 
(Lederfein et al. 1993; Michalak & Opas et al. 2001; Milner et al.  1993; Zubrzycka-Gaarn 
et al. 1988).  
 
Fig. 2. Schematic showing the organization of the human Duchenne muscular dystrophy 
(DMD) gene and the dystrophin-related protein family (Modified from Blake et al. 2002). 
3. Functional evidence of CNS aberrations in dystrophinopathy 
Since the original description of the disease by Duchenne (1868) in which he reported five 
patients with some degree of cognitive impairment there has been debate as to whether there 
is a cognitive deficit associated with DMD. A meta-analysis of 32 studies comprising of 1224 
patients with DMD with full-scale IQ data available for 1146 DMD patients reported an 
average IQ of 80.6 (SD 19.3), which was statistically different from the normal population 
average (Cotton et al. 2001). In this sample 35% of boys had an IQ lower than 70. Of these 79% 
were characterized as mild, 19% moderate, 1% severe and 0.3% profound (Cotton et al. 2001). 
The importance of cognitive impairment in DMD has been demonstrated by a number of 
reports detailing developmental delay as the first presentation of disease (Essex & Roper 2001; 
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Kaplan et al. 1986; Mohamed et al. 2000; Smith et al. 1989). Specific subsets in cognitive ability 
which have been found to be affected in DMD/BMD include: memory/attention/recall (for 
patterns, numbers and verbal labels, serial position), verbal learning, language/verbal 
skills/confrontational naming, phonological and graphophonological production, reading, 
visuospatial organization skills, writing/spelling, comprehension/receptive language, 
mathematics, locomotor areas, verbal expression/fluency and conceptual ability (Anderson et 
al. 1988; Billard et al. 1992, 1998; Bresolin et al. 1994; Cotton et al. 1998; D’Angelo & Bresolin 
2003; Dorman et al. 1988; Hendriksen & Vles 2006; Hinton et al.  2000, 2001; Karagan et al. 
1980; Ogasawara 1989; Palumbo et al. 1996; Savage & Adams 1979; Smith et al. 1989, 1990; 
Sollee et al. 1985; Whelan 1987). Recent evidence suggests that children with DMD may have a 
distinct language-based learning deficit, similar to that seen in developmental dysphonetic-
dyseidetic dyslexia i.e. problems with phonic analysis and synthesis of words as well as 
perception of the visual shape of words (Billard et al. 1992, 1998; Cotton et al. 2001). A number 
of investigators have hypothesized that the cerebellum plays an important role in the 
manifestation of cognitive deficits in dystrophinopathies (Cyrulnik & Hinton 2008; D’Angelo 
& Bresolin 2003; Hendriksen & Vles 2006). 
Individual studies finding a difference between verbal and performance IQ include Karagan 
& Zellweger (1976), Karagan & Zellweger (1978), Karagan (1979), Glaub & Mechler (1987), 
Bresolin et al. (1994), Roccella et al. (2003), and Ogasawara (1989a). In a more recent meta-
analysis VIQ and PIQ data was available for >800 children with VIQ = 80.4 +/- 18.8 (SD, 
n=881) and PIQ 85.4 +/- 16.9 (SD, n=878), both significantly different from the normal 
population. The discrepancy in VIQ and PIQ was –5.1 +/- 14.4 (SD, n=877). The mean was 
significantly different from zero but the distribution did not differ significantly from normal 
and was less than 10, the figure thought to establish clinical significance (Cotton et al. 2001, 
Wechsler 1997). Although there is a statistical difference between these IQ scores the 
functional significance is negligible. 
Gauld et al. (2005) investigated the influence of IQ on the ability of children with DMD to 
perform spirometry, as well as assessing the impact of specific interventions for 
improvement. They found that the mean IQ was 84.7, PIQ 90.6 and VIQ 85.6 in 47 boys 
tested (mean age 12.6 years). The mean parent reported oppositional behaviour score was 
56.3 (range 39 - 87) and mean teacher reported oppositional behaviour score was 56.9 (range 
45 - 90) (higher scores on the scale correlate to children more likely to break rules, have 
problems with authority and who are easily annoyed) (Conners 2000). The oppositional 
behavioural scores remained stable over a 2.3 year period with a test-retest reliability of r = 
0.54 (parent-rated) and r = 0.6 (teacher-rated), P < 0.001 for both (Gauld et al. 2005). They 
found that the results of spirometry testing were related to the individuals’ performance IQ 
and can be explained by difficulties in understanding or learning to perform the technique 
required. The use of computer visualised incentives led to an improvement in function of 
spirometry testing in those shown to have a moderate intellectual or behavioural 
disturbance (Gauld et al. 2005). Additionally, Uchikawa et al. (2004) found in a group of 7 - 
14 year old boys with DMD living in the community, that motor scores were higher in those 
with good cognitive functioning compared to those with impaired cognitive functioning, 
even though muscle strength was not significantly different. The authors note that poor 
cognitive functioning has an adverse effect on activities of daily living in DMD and that this 
impacts training and performance of these activities. These studies demonstrate the 
importance of paying attention to the cognitive functioning of individual patients with 
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DMD, as specific interventions can lead to improved symptom management and quality of 
life. 
The search for a clear genotype-phenotype correlation with the degree of cognitive 
impairment has been confusing with conflicting reports. A recent study has brought some 
clarity to this issue. Taylor et al. (2010) have demonstrated that there is a quasi dose-
response i.e. the cognitive impairment increases with cumulative loss of dystrophin gene 
products. A number of studies have suggested a higher incidence of a variety of 
neuropsychiatric deficits in boys with DMD compared to normal including dysthmic and 
major depressive disorders, anxiety, attention deficit hyperactivity disorder, obsessive-
compulsive disorder and autism spectrum disorder (Fitzpatrick et al. 1986; Hendriksen & 
Vles 2008; Komoto et al. 1984;  Melo et al. 1995; Poysky 2007; Reid & Renwick 2001; Roccella 
et al. 2003; Sekiguchi 2005; Wu et al. 2005; Young et al. 2008; Zwaigenbaum &Tarnopolsky 
2003). As yet Reid & Renwick (2001) have been the only investigators to demonstrate an 
effect of decreased IQ on mental health in the dystrophinopthies, with no reports to 
investigate if the converse is true.  
3.1 Morphological evidence of a CNS deformity in dystrophinopathy 
Morphological studies of the CNS in dystrophinopathy have been inconsistent with some 
investigators reporting no or minimal changes  (Bresolin et al. 1994; Dubowitz and Crome 
1969; Rae et al. 1998), cerebral atrophy in later stages of disease (Al-Qudah et al. 1990; 
Yoshioka et al. 1980), abnormalities in dendritic development and arborisation in visual 
cortical neurons with extensive Purkinje cell loss (Jagadha & Becker 1988) and pachygyria 
(Bandoh et al. 1987; Rosman & Kakulas 1966; Wibawa et al. 2000). Some investigators have 
found a link between morphological abnormalities and impaired cognitive function 
(Bandoh et al. 1987; Bresolin et al. 1994; Rosman & Kakulas 1966; Septien et al. 1991; Wibawa 
et al. 2000; Yoshioka et al. 1980), whilst others have not (Al-Qudah et al. 1990). 
Sogos et al. (1997) disrupted the expression of dystrophin in human neuronal cultures using 
in vitro techniques. They found a disruption of the morphology of synaptic boutons with 
alteration of the neuronal cytoskeleton in these cells. This also assessed whether a lack of 
dystrophin would lead to any perturbations of neuronal NOS (nNOS) using similar 
techniques (Sogos et al. 2003). They found that nNOS messenger RNA was significantly 
decreased (~ 35%) in neurones treated with B-dystrophin antisense. These authors 
postulated that decreased nNOS in neurons deficient for dystrophin may be responsible for 
alterations in synaptic plasticity (due to known association between nNOS and the NMDA 
receptor). Alternatively, the involvement of nNOS in CNS development may mean any 
perturbation could lead to altered neuronal maturation and abnormal synaptogenesis in 
developing neurons (Sogos et al. 2003).  
3.2 Biochemical evidence of a CNS abnormality in dystrophinopathy 
The search for the biochemical mechanisms underlying the cognitive deficit associated with 
lack of dystrophin in humans has been necessarily limited, however, new technologies 
allowing in vivo analysis has enabled some investigations. Not surprisingly oxygen and 
carbon dioxide levels have been found to be abnormal (especially during sleep), thought to 
be due to weakened respiratory function secondary to underlying muscle weakness and rib 
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cage deformation (Khan & Heckmatt 1994; Manni et al. 1991; Misuri et al. 2000; Smith et al. 
1988). Glucose hypometabolism has been studied by a number of groups as it is a common 
feature of disorders with associated cognitive deficits, and is generally indicative of lowered 
synaptic activity (Jueptner & Weiller 1995). Bresolin et al. (1994) found decreased glucose 
uptake in the cerebellum in DMD boys using PET imaging. Lee et al. (2002) using PET and 
MRI found four clusters of decreased glucose metabolism in DMD: medial temporal 
structures and cerebellum bilaterally, the sensorimotor and lateral temporal cortex on the 
right side (compared to an adult control group). The authors suggest that these findings 
may reflect local cytoarchitectural changes and abnormalities associated with altered neural 
development. Tracey et al. (1995), Kato et al. (1997) and Rae et al. (1998) using magnetic 
resonance spectroscopy and autopsy studies (Kato et al. 1997) focussed on choline-
containing compounds which are seen to be elevated in a number of brain disorders and 
interpreted as symptomatic of increased membrane turnover or decreased membrane 
stability (Rae et al. 1998). MRI demonstrated significantly increased choline-containing 
compounds in the cerebellum, but not the cortex of boys < 13 years (Rae et al. 1998). The 
ratio of choline-containing compounds to N-acetylaspartyl-containing compounds 
(Cho/NA) was shown to correlate significantly with scores on the Matrix Analogies Test 
(MAT). The cerebellar and hippocampal focus of the biochemical lesions in DMD are of 
interest, due to the normally high expression of dystrophin in neurons found in these 
regions (Bresolin et al. 1994; Lee et al. 2002; Rae et al. 1998). Both Dorman et al. (1988) and 
Billard et al. (1998) noted that the reading deficits seen in DMD patients are similar to those 
seen in phonological dyslexia (Castles & Coltheart, 1993). Persons with phonological 
dyslexia, either developmental (Nicolson et al. 1999; Rae et al. 1998) or acquired (Levisohn et 
al. 2000), have been shown to have abnormalities in the right cerebellum. Similarly, deficits 
in verbal working memory, a large component of the DMD cognitive deficit (Hinton et al. 
2001) are known to have a cerebellar focus (Desmond et al. 1997). 
3.3 Electrophysiological evidence of a CNS abnormality in dystrophinopathy 
EEG abnormalities have been reported in DMD although the only large study with 
appropriate controls (Barwick et al. 1965) found no association between abnormal EEG and 
dystrophinopathy. To date no studies have examined genotypically confirmed DMD and 
EEG abnormalities although an increased incidence of epilepsy has been noted in boys with 
dystrophinopathies compared to the general population (Etemadifar & Molaei 2004; 
Goodwin et al. 1997). Motor cortex excitability has also been demonstrated to be affected in 
DMD with reduced excitability thought to be due to aberrant synaptic functioning (Bresolin 
et al. 1994; Di Lazzaro et al. 1998; Jueptner & Weiller 1995). 
4. Evidence from animal models of dystrophinopathy: the mdx mouse 
The mdx mouse (muscular dystrophy X-linked) is the most widely studied animal model of 
dystrophinopathy (Collins & Morgan 2003; Durbeej & Campbell 2002; Partridge 1991). 
Although its discovery predated the genotyping of this disorder it has since been proven to 
be an appropriate model with identification of a premature stop codon terminating 
translation of murine dystrophin resulting in an absence of all full-length dystrophin-gene 
products (Bulfield et al. 1984; Chamberlain et al. 1987; Hoffman et al. 1987; Sicinski et al. 
1989). This mouse model has aided in investigations of the function of dystrophin, 
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particularly in the CNS as invasive functional investigations can be carried out on these 
animals. The majority of current knowledge of the role of dystrophin in the CNS comes from 
this animal model.   
4.1 Cognitive functioning 
Impairments in passive avoidance learning, long-term recognition memory and procedural 
learning have all been shown to be adversely affected in mdx mice compared to controls. Task 
acquisition, procedural memory spatial discrimination tasks, novelty-seeking behaviour and 
exploration in an elevated plus maze have all been shown to be unaffected in the mdx mouse 
(Mehler et al. 1992; Muntoni et al. 1991; Perronnet & Vaillend 2010;  Sesay et al. 1996; Vaillend 
et al.  1995, 1998, 1999, 2004). Most recently Sekiguchi et al. (2009) have demonstrated an 
enhanced defensive freezing response to a brief restraint as well as enhanced unconditioned 
and conditioned defensive responses to electrical footshock in mdx mice compared to 
wildtype. This abnormal behaviour was ameliorated with intracerebroventricular 
administration of antisense morpholino oligonucleotide (which induces skipping of the 
premature stop codon located at exon 23 in the mdx mouse and produces a truncated 
dystrophin with a 71 amino acid deletion in the mid-rod domain) (Alter et al. 2006; Sekiguchi 
et al. 2009). 
4.2 Morphology 
No gross abnormalities in brain or spinal cord in the mdx mouse have been found (Bulfield 
et al. 1984; Dunn & Zaim-Wadghiri  1999; Torres & Duchen 1987; Yoshihara et al. 2003). This 
was most recently confirmed using MRI by Miranda et al. (2009) who found no major 
alteration of brain anatomy in mdx mice, reporting no significant changes in the cortex, 
hippocampus or cerebellum (normally dystrophin-positive). At the cellular/axonal level 
dystrophin has been found to localise to the cell membrane, predominately the soma and 
postsynaptic densities particularly in hippocampus, neocortex, cerebellum and amygdale 
(Anderson et al. 2002; Lidov 1996; Perronnet & Vaillend 2010). Anatomical alterations have 
been found in the mdx mouse in various brain regions including decreased cell number, 
altered cell packing density and changes in cell morphology (Carretta et al. 2001; Sbriccoli et 
al. 1995). It should be noted that these changes were not demonstrated when investigated in 
the hippocampus. CA1 pyramidal cell packing density, mean nuclear area and circularity 
has been found to be unaltered in mdx mice (Miranda et al. 2009). PSD length of axospinous 
perforated excitatory synapses has been found to be larger in mdx proximal radiatum of the 
hippocampus (Miranda et al. 2009). These authors note that perforated synapses are the 
hallmarks of activity dependent synaptic plasticity (Miranda et al. 2009). A more recent 
report by this group has demonstrated that the presynaptic ultrastructure of excitatory 
hippocampal synapses is altered in both mdx and Dp71-null mice (Miranda et al. 2011). 
Again examining the proximal radiatum glutaminergic synapses (normally dystrophin-
positive) they report an increased number of docked vesicles, with the number and size of 
vesicles similar in mdx mice compared to controls. They also found a decrease in the number 
of vesicles in the ‘reserve pool’ i.e. > 300nm away from the synapse) in mdx mice compared 
to controls. In the Dp71-null mice they found that the number and spatial distribution of 
vesicles was no different from control (Miranda et al. 2011). In contrast to Dp427-null (mdx) 
mice the number of vesicles in the active zone was decreased and the number of vesicles in  
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the reserve pool was increased compared to controls, whilst the number of docked vesicles 
remained the same. Alterations in parvalbumin-positive and calbindin-positive 
interneurons (both calcium binding proteins) have been demonstrated to be significantly 
increased in particular brain regions of mdx compared to wildtype (Carretta et al. 2003, 
2004). At the receptor level the glucose transporters GLUT1 and GLUT4, α1 and α2 GABAA 
receptor subunit and nicotinic ACh receptor gene expression is decreased in specific brain 
regions of mdx mouse (Wallis et al. 2004). Of particular interest is the strong association of 
dystrophin with the GABAA receptor. Knuesel et al. (1999) found co-localization of the 
GABAA channel with dystrophin in the mouse cerebellum and hippocampus. In these areas 
of the mdx mouse there was a marked reduction of GABAA clusters. This decrease in 
clustering was particularly striking around the soma of cerebellar Purkinje cells. In both the 
cerebellum and hippocampus the number (but not size) of GABAA clusters was reduced by 
~ 50%. Brunig et al. (2002) found that the DGC and GABAA-gephyrin complexes undergo 
different clustering mechanisms and that the DGC is unchanged by the absence of 
gephyrin/GABAA. They suggested that selective signalling from presynaptic GABAergic 
terminals contributes to DGC clustering (Brunig et al. 2002). The authors postulated that the 
DGC may stabilise GABAA clusters, in a developmentally regulated manner. They also 
suggested functions for the DGC at the synapse: i) by stabilizing the postsynaptic apparatus, 
the DGC may “freeze” GABAergic synapses in order to maintain a certain status of the 
network once learning processes have been primarily completed or ii) DGC may provide a 
scaffold enabling changes in clusters of GABAA receptor without incurring the loss of the 
postsynaptic apparatus, as may be required in circuits with a high degree of synaptic 
plasticity. 
Grady et al. (2006) generated α-dystrobrevin, β-dystrobrevin (both members of the DGC) 
and double mutant α – and β-dystrobrevin knockout mice. They examined the localisation of 
α and β-dystrobrevin, finding both proteins in the hippocampus and cerebral cortex. They 
found that all larger β-dystrobrevin-positive puncta on the dendrites (but not somata) of PC 
were colocalised with gephyrin staining (gephyrin is associated with inhibitory synapses in 
the CNS). When staining for the GABAA α1 subunit in β-dystrobrevin knockout mice, they 
found a decrease in the number of GABAA α1-positive clusters of 33% and reduction in size 
by approx 50% in cerebellar PC. This finding is comparable with Knuesel et al. (1999) (no 
such association in the cerebellum of α-dystrobrevin knockout mice was found). They 
further demonstrated that, in mdx mice, a loss of dystrophin led to a loss of dystrobrevin at 
these sites and in dystrobrevin knockout mice, a loss of dystrobrevin led to a loss of 
dystrophin at these sites. This interrelationship between dystrobrevin and dystrophin was 
not demonstrated in the hippocampus. Another member of the DGC – dystroglycan has also 
been demonstrated to be clustered at GABAergic synapses. Dystroglycan deficient mice 
have GABAergic clusters lacking dystrophin, however dystrophin-deficient mice (i.e. mdx) 
as well as gephyrin-deficient mice do not lose colocalisation of dystroglycan and GABAergic 
synapses (Brunig et al. 2002; Levi et al. 2002; Waite et al. 2009). As will be described below 
Kueh et al. (2011) demonstrated that there is a reduction in the number of functional 
receptors localised at the GABAergic synapses in the cerebellar PCs of mdx mice and an 
increase in extrasynaptic GABAA receptors. Vaillend et al. (2010) have demonstrated a re-
expression of a truncated dystrophin in the hippocampus after intra-hippocampal injection 
of adenovirus-associated vector expressing antisense sequences linked to a modified U7 
small nuclear RNA that re-directed the splicing of dystrophin pre-mRNA allowing omission 
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of exon 23 of the dystrophin gene in the mdx mouse. This allows restoration of the reading 
frame and a functional dystrophin protein to be expressed. The levels of expression of the 
truncated dystrophin reached 15-25% of wildtype. They further investigated whether this 
‘rescue’ of dystrophin expression had an impact on GABAA receptor clustering. They found 
that the number of clusters and the area of the α2 subunit of the GABAA receptor was 
significantly larger in the treated mdx mice compared to untreated mdx mice, and was 
actually no longer significantly different from wildtype (Vaillend et al. 2010) suggesting 
complete recovery of GABAA receptor clustering after partial dystrophin-rescue. They 
conclude that although dystrophin is not involved in synpatogenesis it may be important in 
maintenance and stabilisation of postsynaptic GABAA receptors. They note that dystrophin 
is co-localised with α2-containing GABAA receptors at a relatively low rate and postulate 
that the remaining dystrophin may be involved in trafficking/targeting processes, 
expressed in empty synapses transiently devoid of GABAA receptors (Vaillend et al. 2010).   
The overall protein expression levels of GABAA receptors containing α1 subunits in a whole 
membrane preparation of murine cerebellum was investigated by our group and found to 
be no different from littermate controls (Kueh et al. 2008). This finding supports the theory 
that it is the organisation of the GABAA receptor (i.e. altered clustering) rather than the 
expression (i.e. quantity) that is adversely affected by a lack of dystrophin.  
4.3 Biochemistry 
A number of reports have examined metabolites in mdx CNS. Griffin et al. (2001) identified 
discernable changes in metabolic pathways: glycolysis, -oxidation, the TCA cycle, 
phosphocreatine/ATP cycle and lipid metabolism were all altered in mdx cerebral cortex 
and cerebellum. Young mdx mice have been found to have normal levels of N-
acetylaspartate and total creatinine content, increased whole-brain levels of choline-
containing compounds (glycero- and phosphocholine) and myo-inositol, and a decrease in 
the ATP synthase  subunit in cerebellum and hippocampi (Tracey et al. 1996; Wallis et al. 
2004). In older mdx mice a decrease in the total creatinine content, increase in inorganic 
phosphate to phosphocreatine ratio, increased intracellular brain pH, decreased expression 
of mitochondrial creatine kinase in mdx hippocampi, and increased choline containing 
compounds in cerebellum and hippocampus of mdx brain, but not the cortex, have all been 
reported (Rae et al. 2002; Tracey et al. 1996; Wallis et al. 2004). Together these results indicate 
that there are significant differences in mdx mice CNS metabolism possibly indicating 
increased membrane turnover or decreased membrane stability. Furthermore, there is a 
clear exacerbation of these biochemical abnormalities with age, although there is yet no clear 
explanation of how a lack of dystrophin leads to these changes and why some of these 
perturbations are increased and others decreased with age. 
Other reports have looked at glucose utilisation in CNS of mdx mice. Rae et al. (2002) found 
significantly decreased free glucose in mdx, significantly increased fractional enrichment and 
increased flux of 13C into metabolites such as glutamate and GABA. These authors noted 
that this may indicate a faster metabolic rate in dystrophin-deficient brain due to abnormal 
functioning of GABAA receptors and, therefore, decreased inhibition (as, in general, 
excitatory stimulation leads to increased glucose metabolism and inhibitory activation leads 
to decreased glucose metabolism) (Ito et al. 1994; Rae et al. 2000, 2002). In old mdx mice there 
was abnormal metabolism of [1-13C] glucose (Rae et al. 2002). In a follow-on study this 
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group found no significant difference in glucose metabolism in the young mdx mice 
compared to controls, suggesting that changes in glucose metabolism seen in the old mdx 
mice are due to other factors (i.e. not changes in expression of glucose transporters) (Wallis 
et al. 2004).  
AQP4 and osmotic/cellular volume alterations in mdx mice has been reported. Increased 
extracellular and decreased intracellular volume in mdx brain as well as altered 
osmoregulation was reported by Tracey et al. (1996a) and Griffin et al. (2001). Frigeri et al. 
(2001) found that although AQP4 mRNA staining pattern was unaltered, the level of this 
protein was decreased in mdx CNS. This decrease grew with age (70% decrease at 12 
months). Dp71 has been found to be the major dystrophin gene product responsible for 
anchoring AQP4 and the DGC at the glial endfeet (Amiry-Moghaddam et al. 2004; Neely et 
al. 2001; Nicchia et al. 2008; Yokota et al. 2000). Nicchia et al. (2004) reported the 
unpublished observation of Frigeri et al. (2001) that mdx mice also demonstrate a resistance 
to brain oedema. They postulated that the absence and/or mislocalisation of AQP4 at the 
perivascular endfeet is protective in induced brain oedema. Nico et al. (2003) found a 
profoundly altered blood-brain-barrier (BBB). Although initial reports suggested no 
alteration in response to osmotic stress (hypo-osmotic shock) in mdx CNS (Rae et al. 2002). 
Vajda et al. (2002, 2004) found, in osmotic stress experiments, that the mdx-geo mice had a 
delayed decompensation and increased survival time (66.5 min compared to 56 min) 
indicating that Dp71 is necessary for the polarized distribution of AQP4 in brain. 
Interestingly, many of these reports propose a link between the biochemical abnormalities 
and underlying channel dysfunction secondary to a lack of dystrophin. Rae et al.’s (2002) 
report suggests that the increased glucose use demonstrated in mdx brain may be due to 
decreased inhibitory input from the subset of abnormally clustered GABAA-receptors. 
Further Griffin et al. (1999) have proposed this elevation is associated with cellular 
membranes implying a progressive, degenerative or compensatory process (Rae et al. 2002).  
Decreased bioenergetic buffering capacity would be expected to influence susceptibility to 
hypoxia. Mehler and coworkers (Mehler et al. 1992) reported an increase in sensitivity of 
hippocampal slices from mdx mice to loss of synaptic transmission of CA1 hippocampal 
pyramidal cells during hypoxia. This was partially ameliorated by blocking both sodium-
dependent action potentials as well as low-threshold calcium conductances. Yoshihara et al. 
(2003) suggested that the increased sensitivity to hypoxia found by Mehler et al. (1992) may 
be due to impaired function of inhibitory synapses at this site. Another group (Godfraind et 
al. 1998, 2000) has shown increased susceptibility of mdx hippocampal tissue slices to 
irreversible hypoxic failure when kept in 10 mM glucose, but less susceptibility of mdx slices 
when kept in 4 mM glucose, in agreement with Wallis et al. (2004). The latter group suggest 
that the decrease in GLUT1 and GLUT3 expression they found is most likely related to 
decreased synaptic integrity, resulting in decreased activity and decreased glucose 
utilization. These authors noted that dystrophin may be required to maintain synaptic 
integrity (Knuesel et al. 2001) rather than being directly involved in anchoring/clustering of 
the GABAA receptor itself. Additionally, it is known that the expression of components of 
the GABAA receptor relate to synaptic activity (Ives et al. 2002). Thus, Wallis et al. (2004) 
proposed that the lack of dystrophin in the PSD may impede synaptic activity leading to 
decreased GABAA receptor components due to decreased GABAergic demand. Wallis et al. 
(2004) suggested that dystrophin may be involved in the clustering of this complex of 
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proteins (mitochondrial creatine kinase, adenine nucleotide translocase and the gamma 
subunit of ATP synthase). Furthermore, Rae et al. (2002) suggested that the regulation of 
oxidative metabolism during hypoxia was impaired, and that this may be another 
manifestation of calcium overload in the neuronal mitochondria of mdx CNS. 
4.4 Electrophysiology 
The highest levels of dystrophin gene products are in areas in which neurons maintain a 
high degree of synaptic plasticity: olfactory bulb, hippocampus, neocortex and cerebellum 
(Gorecki et al. 1997, 1998; Lidov et al. 1990). Synaptic plasticity has been examined in both 
the hippocampus and cerebellum and found to be altered in the mdx mouse in both of these 
brain regions (Anderson et al. 2004, 2010; Vaillend et al. 1998, 1999, 2004). Vaillend’s group 
examined the CA1 dendritic layer of the hippocampus and found that NMDA-receptor 
dependent short-term and long-term potentiation, and long-term depression were 
abnormally enhanced in mdx mice (Perronnet & Vaillend 2010; Vaillend et al. 1998, 1999, 
2004). Both our and Vaillend’s group have investigated the function of the GABA receptor in 
the mdx cerebellum and hippocampus respectively as it is known to colocalise with 
dystrophin (Knuesel et al. 1999). In mdx mice hippocampus and cerebellum there is a 
marked reduction of GABAA clusters, with the number (but not size) of GABAA clusters 
being reduced by ~ 50% (Knuesel et al. 1999). In both the cerebellum and hippocampus the 
GABAA antagonist had a decreased effect (Anderson et al. 2003; Vaillend et al. 2002). When 
miniature inhibitory postsynaptic potentials were examined in the cerebellum a decrease in 
frequency and amplitude was found in contrast to the hippocampus where an increase in 
frequency was demonstrated (Anderson et al. 2003; Kueh et al. 2008; Graciotti et al. 2008). 
We have noted however that the reduction in amplitude may lead to a falsely lowered 
frequency due to lowered amplitude IPSCs being below counting threshold. These results 
have led to the ‘dysfunctional inhibition’ hypothesis being postulated as the cause of the 
cognitive impairment seen in DMD (Perronnet & Vaillend 2010). Dallerac et al. (2011) 
demonstrated that mdx mice treated with U7 small nuclear RNAs modified to encode 
antisense sequences and expressed from recombinant adeno-associated viral vectors to 
induce skipping of the premature stop codon at exon 23 of the dystrophin gene normalises 
hippocampal synaptic plasticity. The vector was injected into the hippocampus and months 
after two months CA1 hippocampal LTP, which is normally enhanced compared to 
wildtype, was no longer different from wildtype.  In studies of seizure induction in mice, 
dystrophin deficiency has been found to alter the neuronal excitability of AMPA/kainic-
type glutamate receptors suggesting a dysfunctional excitatory-inhibitory balance (De Sarro 
et al. 2004; Perronnet & Vaillend 2010; Yoshihara et al. 2003). Basolateral nucleus of the 
amygdale pyramidal neurons have also been studied in the mdx mouse and have been 
demonstrated to have decreased inductions of GABA-ergic IPSCs by noradrenalin. These 
authors note that in the mdx there were cells sensitive to noradrenalin (~40%) and a larger 
subset of cells insensitive to noradrenalin (~60%). Whilst the regular-spiking non-pyramidal 
basolateral nucleus of the amygdale neurons had similar proportions of noradrenalin-
induced depolarisation and AP firing (~50%) in wildtype and mdx demonstrating that the 
mechanism by which noradrenalin  depolarises interneurons  beyond AP threshold is not 
impaired in mdx mice. Rather it is more likely that a decrease in the number of normal 
functioning GABAergic synapses between the noradrenalin-responsive interneurons and 
pyramidal neurons underlies their findings (Sekiguchi et al. 2009). 
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Work from our laboratory has similarly demonstrated altered GABA-ergic function in the 
cerebellum of mdx mice. We found that evoked excitatory post-synaptic potentials in 
cerebellar Purkinje cells show a decreased response (approx 50%) to bicuculline (a GABA 
antagonist) compared to wildtype (Anderson et al. 2003). We also demonstrated that 
miniature inhibitory postsynaptic currents had a significantly decreased amplitude in mdx 
cerebellar Purkinje cells compared to wildtype. This difference in amplitude was principally 
due to the absence of large amplitude miniature inhibitory postsynaptic currents in mdx 
mice. We postulate that this decrease is the result of a decrease in the number of 
postsynaptic GABA-ergic receptors (Nusser et al. 1997). This finding was reproduced in 
later studies (Fig. 3; Kueh et al. 2008,  2011). We further went on to investigate the number of 
GABAA channels located at the GABAergic synapse of cerebellar Purkinje cells. We found a 
significant reduction in the number of receptors at the PSD in mdx compared with littermate 
controls determined by non-stationary noise analysis of spontaneous miniature inhibitory 
postsynaptic currents. Single unitary conductance, rise and decay times of the currents were 
no different from littermate controls demonstrating that although there is a reduction in the 
number of channels at the postsynaptic membrane in mdx cerebellar Purkinje cells, the 
GABAA channels that are present are functioning normally. Further, Gaboxadol, an 
extrasynaptic GABA agonist, was applied inducing an increase in the holding current of the 
Purkinje cell. In mdx mice this increase was significantly greater (~200%) compared to 
littermate controls (Kueh et al. 2011), indicating that in mdx mice the number of 
extrasynpatic GABAA receptors is increased. 
 
Fig. 3. A scatter plot of rise time versus peak amplitude, showing the distribution of mIPSCs 
in a (i) mdx and a (ii) littermate control mouse. The inserts show a section of the recording in 
aCSF and when TTX was added to the bath.  iii) Cumulative probability of mIPSC 
amplitudes (average) in mdx and littermate control cells. There was a significant difference 
between mIPSC amplitudes between mdx and litermate control cells (Mann Whitney test, 
p=0.0001) (Modified from Kueh et al. 2011). 
Our group has also investigated synaptic plasticity in the mdx cerebellum which is uniquely 
suited to these investigations as the Purkinje cell – the major output neuron of the 
cerebellum normally expresses a specific full-length dystrophin – P-dystrophin, which is 
absent in mdx mice. The major inputs to the Purkinje cells – parallel fibres and inhibitory 
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interneurons are normally dystrophin negative. Firstly we examined a presynaptic form 
of synaptic plasticity in the cerebellum – short-term synaptic plasticity mediated at  
the parallel-fibre to Purkinje cell synapse. We found no difference between wildtype and 
mdx mice in this form of plasticity as expected due to the post-synaptic localisation of  
 
Fig. 4. Long-term depression (LTD) in cerebellar Purkinje cells of wild-type and mdx mice. 
Upper graph shows the average slope of evoked EPSPs in wild-type and mdx Purkinje cells 
before and after LTD induction. Open circles are wildtype Purkinje cells (n=11) and closed 
circles are mdx Purkinje cells (n=12). Slopes are normalised to the average slope for wild-
type and mdx cells respectively recorded in the 10 minutes preceding LTD induction. Thin 
horizontal bars above the abscissa represent the two 10 minute time periods during which 
the EPSP slopes were averaged and represent the magnitude of early and late phases of 
LTD.  Vertical bars are SEM and for clarity are shown on one side of the data points only. 
Lower bar graph displays the average slope for all wild-type and all mdx cells in the early 
and late phases following LTD induction (Modified from Anderson et al. 2004) 
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dystrophin. We then went on to examine a post-synaptic mediated form of synaptic 
plasticity – long-term depression. As postulated the extent of depression was decreased in 
mdx cerebellar Purkinje cells compared to wildtype (Fig, 4; Anderson et al. 2004). We next 
examined homosynaptic longterm depression at this synapse and found that there was no 
difference between wildtype and mdx cerebellar Purkinje cells in the initial observation 
period, however the depression was significantly greater in the latter part of the observation 
period in mdx compared to wildtype (Anderson et al. 2010). The three most compelling 
explanations for the differences demonstrated above are i) an alteration in calcium 
homeostasis, ii) an indirect effect of altered GABAA receptor localisation and/or trafficking 
and iii) an alteration in putative AMPA-receptor localisation/trafficking. The most recent 
investigations of the multiplicity of effects of the known GABAA receptor dysfunction on the 
neurophysiology of the mdx mouse is compelling. 
Further unpublished data from our laboratory has demonstrated that that short term synaptic 
plasticity (inhibitory interneuron to Purkinje cell synapse) is no different between mdx and 
wildtype. However rebound potentiation – a form of longterm synaptic plasticity expressed at 
this synapse is significantly different. Wildtype cerebellar Purkinje cells demonstrated 
potentiation of the inhibitory postsynaptic potential as previously reported, however the mdx 
cerebellar Purkinje cells depressed. In a pilot study 5/12 wildtype cerebellar Purkinje cells 
demonstrated rebound potentiation (0 depressed) compared to 0/5 mdx cells demonstrating 
potentiation and 4/5 cells demonstrating depression. Although preliminary, these findings are 
the first to demonstrate a deficit in GABA-mediated synaptic plasticity. These findings also 
locate the problem at the post-synaptic (dystrophin-deficient Purkinje cell) locus as the 
presynaptically-mediated short-term synaptic plasticity of this synapse is preserved. 
(Anderson 2009). 
5. Conclusion 
The role of dystrophin in the CNS is complex and incompletely understood. It is clear that 
the absence of this protein leads to profound functional deficits at the macro-level 
(behavioural alterations and cognitive impairment) as well as the micro-level (alterations in 
synaptic plasticity, GABA-ergic functioning). Morphologically there are alterations in 
cellular architecture and organisation as well as channel localisation. The increase in 
investigations of the role of dystrophin in the CNS has led to a rapid appreciation of the 
consequence of its absence in this tissue, however a clear mechanism by which these 
alterations occur has yet to emerge. The majority of current evidence points convincingly to 
a link between a lack of dystrophin and alterations in the localisation of GABAA receptors. 
Furthermore there is evidence that a lack of dystrophin is associated with abnormal 
functioning of GABAA receptor-mediated cellular activity as measured by changes in 
amplitude of IPSCs. The well-established cognitive-impairment seen in the boys with 
dystrophinopathies may be due to an underlying abnormality in synaptic plasticity as 
demonstrated in the mdx animal models. However evidence linking the alteration in GABA-
ergic localisation and function with alterations in synaptic plasticity is speculative. The 
postulated dysfunctional excitatory-inhibitory balance – perhaps mediated by chronic 
alteration of calcium-handling by these neurons, is the most compelling hypothesis to date 
linking these two major findings (alterations in GABA clustering and function with 
alterations in synaptic plasticity).  Further how a lack of dystrophin leads to the structural 
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alterations seen in found in mdx CNS, as well as the plethora of biochemical alterations in 
seen in both humans and animal models of DMD has yet to emerge. The role of the smaller 
dystrophin gene products in the brain are now beginning to be appreciated with a recent 
report demonstrating that a loss of the smallest of these – Dp71, can lead to changes at the 
behavioural, cell membrane and synaptic levels (Daoud et al. 2009). The role of dystrophin 
and the dystrophin-glycoprotein complex in the CNS is slowly being elucidated. With a 
greater understanding of the function of this protein useful therapies may be able to 
ameliorate the CNS manifestations of Duchenne muscular dystrophy as well as aid in the 
effort to arrest the devastating muscular degeneration.    
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